Survival and predictors of mortality among HIV-positive children on antiretroviral therapy in public hospitals

Yalemgeta Biyazin1,2*, Kalkidan Wondwossen1, Azene Bantie Wubie2, Melese Getachew2* and Bereket Gebremichael1

Abstract

Background: Human immunodeficiency virus and acquired immunodeficiency syndrome had created enormous challenges worldwide, and continues to be the world's serious health and development challenges. Globally, at the end 2017, there were 1.8 million children (< 15 years) living with HIV. The survival of HIV-positive children treated with ART depends on a variety of factors, which might vary greatly with economic, socio-demographic, behavior risk, and health factors. This study aimed to assess survival status and predictors of mortality among HIV-positive children on antiretroviral therapy at East Gojjam Zone Public hospitals, Northwest Ethiopia.

Methods: An institution-based retrospective cohort study was conducted in selected hospitals of the East Gojjam zone, Northwest Ethiopia, among < 15-year-old children who were newly enrolled in HIV care clinic from January 1st, 2014 to December 31, 2018. Data were collected from patient charts from March 1 to 22, 2019 using a standardized checklist. Data were analyzed by SPSS version 24. A Kaplan–Meier curve and log-rank test were used to estimate the survival time and compare survival curves between variables. Multivariable Cox proportional-hazards model was fitted to identify predictors of survival status taking p-value < 0.05 as statistically significant.

Result: In this study, a total of 251 HIV-positive children on ART were followed up for a total of 60 months, with a mean survival time of 55.54 (± 0.84) (95% CI: 53.90–57.17) months. The overall mortality incidence rate in the cohort during the 626 Child-Year-Observation (CYO) was 2.56/100 CYO. The overall estimated survival probability after starting ART was 0.90 at 60 months of follow-up. In this study age < 5 years, Hgb < 10 gm/dl, CD4 count below threshold, cotrimoxazole preventive therapy, and subnormal weight for height were statistically significant predictors of survival status (P < 0.05).

Conclusion and recommendation: Age, hemoglobin level, CD4 count, weight for height, and not taking cotrimoxazole preventive therapy were independent predictors of mortality. Therefore, concerned stakeholders should focus on the above-mentioned predictors of mortality and nutritional interventions to enhance the survival of HIV-infected children on antiretroviral therapy.
Background

Human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) have created enormous challenges worldwide. HIV has become one of the world’s most serious health and development challenges since the first cases were reported in 1981. According to UNAIDS (2022), 84.2 million people have become infected with HIV and 40.2 million have been died since the start of the epidemic. In 2021 there were 38.4 million people living with HIV/AIDS out of which children (< 15 years old) comprise 1.7 million cases [1, 2]. In Ethiopia, around 610,000 people were living with HIV of which 42,000 were children (0–14 ages) in 2021 [11–18 UNAIDS].

More than 90% of pediatrics HIV infection occurs through mother-to-child transmission which implies that global distribution of pediatrics HIV infection is similar with the distribution of HIV in women [4]. Infants and young children infected with HIV have exceptionally higher morbidity & mortality. Up to 52% and 75% of children die before the age of two and five years, respectively, in the absence of any intervention [6]. ART should be initiated for all children living with HIV regardless of WHO clinical stage or at any CD4 cell count [3]. However, only 52% of all children aged 0–14 years living with HIV had access to treatment globally in 2021 [1].

The vast majority of people living with HIV are located in the low- and middle-income countries. The first evidence of HIV infection in Ethiopia was detected in 1984. Since then, AIDS has claimed the lives of millions and has left behind hundreds of thousands of orphans. HIV/AIDS epidemic has remained one of the important public health challenges [4]. Ethiopia has one of the largest populations of HIV-infected people in the world [5]. Over the last several years, there has been a dramatic decline in new pediatric infections, but children born infected with HIV are in critical need of lifesaving HIV treatment.

Predictors of mortality among children on HAART in the country were inconsistently reported by fragmented studies conducted in different study areas [6–13]. The survival of HIV-positive children treated with ART depends on a variety of factors, which might vary greatly with economic, socio-demographic, behavioral risk and health factors. Even though ART has shown significant clinical importance by meeting the goal of therapy, still children were facing a number of deaths that could be avoided by appropriate interventions on certain factors such as socio-economic, demographic, treatment-related and health factors which include the child’s age, CD4 count/CD4% at ART initiation, WHO stage, hemoglobin level, ART adherence [14–20].

No study was conducted about the survival and predictors of mortality among HIV-infected children on ART in East Gojjam zone. The aim of this study was; therefore, to assess survival status and predictors of mortality among HIV-positive children on antiretroviral therapy in public hospitals of East Gojjam zone.

Methods

Study setting, design, and period

An institutional based retrospective cohort study was conducted at Debre Markos Referral Hospital (DMRH) and Shegaw Mota District Hospital among children less than 15 years who were living with HIV and initiated for ART from January 1st 2014 to December 31st, 2018. According to 2007 Census, East Gojjam zone has a total population of 2,153,937, of whom 1,066,716 are men, with an area of 14,004.47 square kilometers. It has a population density of 153.80, while 213,568 or 9.92% are urban inhabitants [21].

These two hospitals were purposively selected because they were the only hospitals in the study area which provide ART services at starting time of study period. Debre Markos Referral Hospital is the only referral hospital in East Gojjam zone which is found in Debre Markos town. Shegaw Mota District Hospital (SMDH) is one of primary hospitals in east Gojjam zone which is found in Mota town. According to information obtained from administrative offices of these hospitals, DMRH and SMDH serve more than 3.5 million and 1.5 million populations in their catchment area, respectively [21–23].

Study population

All medical records of HIV-positive children who attended the ART unit of DMRH and SMDH from January 1st, 2014–December 31st, 2018 were considered for inclusion. All HIV-positive children less than 15 years old and who were newly enrolled on ART were included; whereas, children whose medical charts were not found during data collection and/or children’s chart having incomplete data on major variables of the study were excluded.

Sample size and sampling procedure

The sample size was determined using double population proportion formula by considering the covariates. Three variables (INH prophylaxis, baseline CD4 count, and hemoglobin level) that were reported as predictors of

Keywords: Children, Antiretroviral therapy, HIV, Survival, Ethiopia
mortality among children on ART based on study done in Arba Minich, Ethiopia [8] were used to calculate sample size. When calculated with Epi info version 7 statistical package, baseline CD4 count below the threshold ($P_1 = 20.99$ and $P_2 = 11.25$) gave the maximum sample size (486). Percentage in exposed ($P_1 = 20.99$), percentage in non-exposed ($P_2 = 11.25$), a confidence level of 95% ($Z_{A/2} = 1.96$), and one-to-one exposed to non-exposed ratio ($r$) were considered. Charts of children enrolled on ART during the study period were recruited by census as their number was small number of than that obtained from the calculated sample (486). Finally, the selected medical charts were reviewed from March 1 to 22, 2019.

**Study variables**
Survival status was dependent variable of this study. The different independent variables used were socio-demographic factors (age at initiation of ART, sex, residency, primary caregiver, and caregiver religion), clinical and laboratory factors (baseline WHO stage, tuberculosis (TB) positive at baseline, CD4 count/percent at baseline, past opportunistic illness, and hemoglobin level), treatment-related factors (early/delayed initiation, baseline ART regimen, OI prophylaxis, ART adherence, and drug side effects), and nutritional factors (underweight, stunting, and wasting).

**Data collection**
A data abstraction format was developed in English language from the standardized ART entry and follow-up form that is currently used by the ART clinics of the study hospitals. It contains three parts; socio-demographic information and nutritional information, clinical and laboratory information, and treatment-related information. The starting point for retrospective follow-up was the time from initiation of ART, and the end point was date of death, date of lost to follow-up, date of transfer out or date of last contact until January 31$^{th}$, 2018. Before collecting the data, the records were reviewed (both baseline and follow-up records). Death was confirmed by death certificate complemented by registration and were identified by their medical record number. The most recent laboratory test results before starting ART were used as a baseline value. If there is no pre-treatment laboratory test, results obtained within one month of ART initiation were used as a baseline. In cases where there were two results obtained within a month, the mean value was used.

**Data quality control**
To ensure quality of the data, pretest was conducted with 5% of the sample population in Finote Selam Hospital found in west Gojam Zone, Amhara regional state. Four nurses, who have been working on ART unit, participated in data collection. One supervisor in each hospital was assigned to closely supervise the entire data collection process. Training on record review was given to data collectors and supervisors for one day before actual data collection task. All completed data collection forms were examined for completeness and consistency during data management, storage, cleaning and analysis. Consistency was examined through random selection of cards by the principal investigator and cross-checked for their similarity. The overall data collection process was under control of the principal investigator. The data were entered and cleaned by principal investigator before analysis.

**Data analysis**
Data were coded and then entered to EPI-data 3.5.3 and transferred to SPSS v 24 statistical software for analysis. Data exploration was undertaken to see if there are odd codes or items that were not logical and then subsequent corrections were made. The actuarial life table was used to estimate probabilities of survival after ART initiation at different time intervals. Kaplan–Meier survival curve together with log-rank test was used to check the presence of difference in survival among categories of covariates and log-rank test was used to compare survival curves. Cox regression was carried out to find predictors of survival status. Patient’s cohort characteristics were described in terms of central tendency and dispersion value for continuous data, and frequency distribution for categorical data. Finally, the outcome of each subject was dichotomized into censored or death. Bivariate Cox regression was first fitted and those independent variables which became significant on the bivariate regression was dichotomized into censored or death. Bivariate Cox regression having $p$-value $\leq 0.25$ level of significance were included in the multivariable analysis. Cox proportional-hazard regression was fitted at 5% level of significance to determine the net effect of each explanatory variable on time to death after ART initiation (hazard ratio with its 95% confidence interval and p-values was used to measure strength of association and identify statistically significant result). $P$-value $< 0.05$ was considered as statistically significant association. Finally, the results of the study were presented with text, graph and table.

**Operational definitions**

**Censored**
Those HIV-positive children who did not develop the outcome of interest (death) until the end of follow-up period, those lost to follow-up or transferred out to a different care unit during the study.

**Children**
A group of individuals aged less than 15 years.
**Duration on ART**

Is defined as the time between the start date of ART and the date of last contact with the health facility.

**Event**

The occurrence of death from initiation ART to the end of the study.

Medication adherence: was classified as Good (95% or ≤ 2 missed drug doses of 30 doses or < 3 missed drug doses of 60 doses); Fair (drug adherence of 85–94% or 3–5 missed drug doses of 30 doses or 4–9 missed drug doses of 60 doses); and Poor (drug adherence of < 85% or ≥ 6 doses of missed ART drug doses of 30 doses or > 9 doses missed ART drug doses of 60 doses) [24].

**Moderate stunting**

Children having height/age Z-score < − 2 SD [25, 26].

**Moderate underweight**

Children having weight/age Z-score < − 2 SD [25, 26].

**Moderate wasting**

Children having weight/height Z-score < − 2 SD [25, 26].

**Severe stunting**

Children having height/age Z-score < − 3 SD [25, 26].

**Severe underweight**

Children having weight/age Z-score < − 3 SD [25, 26].

**Severe wasting**

Children having weight/height Z-score < − 3 SD [25, 26].

**Survival status**

In this research, survival status was defined as the outcome of patients was sourced from patient clinical data files and was dichotomized into censored or death.

**Ethical considerations**

Ethical clearance letter was obtained from Institutional Review Board of School of Nursing and Midwifery, College of Health science, Addis Ababa University. Permission was obtained from Debre Markos referral hospital and Shegaw Mota district hospital. All collected data were coded to keep the confidentiality. Names and unique numbers of patients were not included in the data collection format, and the data were not disclosed to any person other than the investigators.

**Results**

**Socio-demographic characteristics**

In this study, a total of 251 HIV-positive children on ART were followed up for a total of 60 months (January 1st, 2014–December 31st, 2018). Among HIV-positive children (age 0–14 years), who were initiated for ART from January 1, 2014 to December 31, 2018, 264 records were reviewed. Of these, 251 (95.4%) of records were used in the final analysis, while the remaining 12 (4.6%) records were not included in the final analysis due to missing data from the files. About half (51.8%) of the study participants were males and more than half (57%) of them were from urban areas. The mean and median (SD) age of the children at ART initiation was 89.13 and 96 (± 47.5) months, respectively. The majority of study participants (82.1%) were living with their parents and nearly two-thirds (64.5%) of their caregivers were married. The majority of study participants

| Variable                          | Outcome of the child |
|-----------------------------------|----------------------|
|                                  | Death n(%) | Censored n(%) | Total n(%) |
| **Age (months)**                  |            |               |            |
| < 12                              | 4 (25)     | 15 (64)       | 19 (76)    |
| 12–59                             | 6 (37.5)   | 47 (20.0)     | 53 (21.1)  |
| 60–179                            | 6 (37.5)   | 173 (73.6)    | 179 (71.3) |
| **Sex**                           |            |               |            |
| Male                              | 6 (37.5)   | 124 (52.8)    | 130 (51.8) |
| Female                            | 10 (62.5)  | 111 (47.2)    | 121 (48.2) |
| **Residence**                     |            |               |            |
| Urban                             | 11 (68.8)  | 132 (56.2)    | 143 (57.0) |
| Rural                             | 5 (31.3)   | 103 (43.8)    | 108 (43.0) |
| **Primary caregiver**             |            |               |            |
| Parents                           | 13 (81.3)  | 193 (82.1)    | 206 (82.1) |
| Relatives                         | 2 (12.5)   | 33 (14.0)     | 35 (13.9)  |
| Guardian and orphan               | 1 (6.3)    | 8 (3.4)       | 9 (3.6)    |
| **Religion of caregiver**         |            |               |            |
| Orthodox                          | 13 (81.5)  | 183 (77.9)    | 196 (78.1) |
| Muslim                            | 2 (12.5)   | 42 (17.9)     | 44 (17.5)  |
| Catholic                          | 1 (6.3)    | 3 (1.3)       | 4 (1.6)    |
| Protestant                        | –          | 7 (3.0)       | 7 (2.8)    |
| **Current status of parents**     |            |               |            |
| Both alive                        | 10 (62.5)  | 180 (76.6)    | 190 (75.7) |
| Mother alive, father died         | 3 (18.8)   | 31 (13.2)     | 34 (13.5)  |
| Father alive, mother died         | 1 (6.3)    | 13 (5.5)      | 14 (5.6)   |
| Both died                         | 2 (12.5)   | 11 (4.7)      | 13 (5.2)   |
| **Marital status of caregiver**   |            |               |            |
| Single                            | 1 (6.7)    | 21 (9.2)      | 22 (9.0)   |
| Married                           | 8 (53.3)   | 154 (67.2)    | 162 (66.4) |
| Divorced                          | 5 (33.3)   | 31 (13.5)     | 36 (14.8)  |
| Widowed                           | 1 (6.3)    | 16 (7.0)      | 17 (7.0)   |
| Separated                         | –          | 7 (3.1)       | 7 (2.9)    |
(78.1%) were orthodox Christian religion followers (Table 1).

**Clinical, laboratory and ART information**

Of the total 251 cohorts, 155 (66.80%) children started ART being in mild WHO clinical disease stage of HIV (I or II). After ART initiation, 75 (29.9%) of the children had opportunistic infection. About three-fourths (74.1%) of under-5 years children had appropriate developmental status at ART initiation while 67% of children aged 5–14 year perform their daily activity. Nearly three-fourths (74.1%) of under-5 years children had appropriate developmental status at ART initiation while 67% of children aged 5–14 year perform their daily activity. Nearly three-fourths (73.6%) of the children had CD4 count or percent above the threshold for severe immunodeficiency. Similarly, three-fourths 72.9% of the children have been taking cotrimoxazole preventive therapy. Fifty-one (20.1%) of children were anemic at ART initiation. Majority of children 217 (86.5%) had good ART adherence (Table 2).

Regarding baseline opportunistic infection, diarrhea was the most prevalent infection encountered by 32 (12.5%) participants. Pneumonia (11.55%) and candidiasis (11.95%) were the second and third most common opportunistic infections, respectively (Fig. 1).

Regarding ART regimen, 115(45.8%) of children have taken a drug of AZT-3TC-NVP followed by 42(16.7%) of children have taken a drug of AZT-3TC-EFV (Fig. 2).

In this study, the nutritional status of the study participant showed that, 67(26.3%) were wasted, 72(29.5%) were stunted and 80 (31.9%) were underweight (Table 2).

**Survival status of children on ART**

In this study, a total of 251 HIV-positive children on ART were followed up for a total of 60 months, with a mean (SD) survival time of 55.54 (± 0.83) months (95% CI:53.90–57.17). The overall mortality incidence rate in the cohort during the 626 child-year-observation (CYO) was 2.56/100 CYO. Kaplan–Meier estimation of survival showed that overall estimated survival after starting ART was 90% at 60 months of follow-up. The estimated cumulative survival was 0.98, 0.96, 0.92, and 0.90 at 12, 24, 36, and 60 months, respectively. Sixteen (6.37%) patients died in the study period, but 235 (93.62%) were censored till the end of the study. Among these, 199 (79.3%) were alive, 16 (6.37%) were lost to follow-up, and 20 (8%) were transferred to other health facilities. On the Kaplan–Meier survival curve for time to death of the child on ART, the probability of survival decreases as the follow-up time increases. This study showed that the highest rate of mortality was encountered between 30 and 36 months after initiation of ART (Fig. 3).

**Survival time of children on ART**

In this retrospective cohort study, the mean survival time for the younger children had a shorter survival time than

| Variable                          | Outcome of the child |
|-----------------------------------|----------------------|
|                                  | Death n(%) | Censored n(%) | Total n(%) |
| **Baseline WHO stage**            |            |             |            |
| Stage I                           | 3 (18.8)   | 84 (35.7)   | 87 (34.7)  |
| Stage II                          | 3 (18.8)   | 65 (27.7)   | 68 (27.1)  |
| Stage III                         | 5 (31.3)   | 61 (26.0)   | 66 (26.3)  |
| Stage IV                          | 5 (31.3)   | 25 (10.6)   | 30 (12.0)  |
| **CD4 count at baseline**         |            |             |            |
| Below threshold                   | 12 (75)    | 174 (77.0)  | 186 (73.6) |
| Above threshold                   | 4 (25)     | 10 (17.2)   | 51 (20.5)  |
| **Hemoglobin level**              |            |             |            |
| < 10 mg/dl                        | 11 (68.8)  | 40 (17.2)   | 51 (20.5)  |
| ≥ 10 mg/dl                        | 5 (31.2)   | 193 (82.8)  | 198 (79.5) |
| **Functional status for age ≥ 5 years** | | | |
| Working/functional                | 2 (28.57)  | 130 (68.4)  | 132 (67.0) |
| Ambulatory                        | 1 (14.29)  | 53 (27.9)   | 54 (27.4)  |
| Bedridden                         | 4 (57.14)  | 7 (3.7)     | 11 (5.6)   |
| **Developmental status at baseline for age < 5 years** | | | |
| Appropriate                       | 6 (66.67)  | 34 (75.6)   | 40 (74.1)  |
| Delayed                           | 2 (22.22)  | 7 (15.6)    | 9 (16.7)   |
| Regressed                         | 1 (11.11)  | 1 (8.9)     | 5 (9.3)    |
| **Cotrimoxazole prophylaxis**     |            |             |            |
| Yes                               | 5 (31.25)  | 178 (75.7)  | 183 (72.9) |
| No                                | 11 (68.75) | 57 (24.3)   | 68 (27.1)  |
| **Opportunistic infections**      |            |             |            |
| Yes                               | 10 (62.5)  | 65 (27.7)   | 75 (29.9)  |
| No                                | 6 (37.5)   | 170 (72.3)  | 176 (70.1) |
| **ART adherence**                 |            |             |            |
| Good                              | 8 (50)     | 209 (88.9)  | 217 (86.5) |
| Fair                              | 2 (12.5)   | 17 (7.2)    | 19 (7.6)   |
| Poor                              | 6 (37.5)   | 9 (3.8)     | 15 (6.00)  |
| **Drug side effect**              |            |             |            |
| Yes                               | 4 (25)     | 57 (24.3)   | 61 (24.3)  |
| No                                | 12 (75)    | 178 (75.7)  | 190 (75.7) |
| **The regimen changed**           |            |             |            |
| Yes                               | 5 (31.25)  | 10 (4.3)    | 15 (6.0)   |
| No                                | 11 (68.75) | 225 (95.7)  | 236 (94.0) |
| **Weight for height**             |            |             |            |
| Normal                            | 6 (37.5)   | 178 (75.7)  | 184 (73.3) |
| Moderate wasting                  | 4 (25.0)   | 52 (22.1)   | 56 (22.3)  |
| Severe wasting                    | 6 (37.5)   | 5 (2.1)     | 11 (4.4)   |
| **Height for age**                |            |             |            |
| Normal                            | 6 (37.5)   | 171 (72.8)  | 177 (70.5) |
| Moderate stunting                 | 6 (37.5)   | 56 (23.8)   | 62 (24.7)  |
| Severe stunting                   | 4 (25.0)   | 8 (3.4)     | 12 (4.8)   |
| **Height for age**                |            |             |            |
| Normal                            | 6 (37.5)   | 165 (70.2)  | 171 (68.1) |
| Moderate underweight              | 6 (37.5)   | 59 (25.1)   | 65 (25.9)  |
those of older children. The mean (SD) survival time for children aged less than one year were 39.12 (± 4.25) months with 95% CI:30.80–47.45, and the mean (SD) survival time for 5–14 years age group was 57.27 (± 4.69) with 95% CI:55.92–58.63 months. This difference was statistically significant with \( p \)-value < 0.001.

The mean (SD) survival time for those who have been taking cotrimoxazole preventive therapy (CPT) was found to be 57.47(±0.68) months as compared to those who were not taking cotrimoxazole preventive therapy with a mean (SD) survival time of 51.06 (± 1.93) months. This difference is statistically significant with \( p \)-value = 0.003.

Study participants who had a low hemoglobin level (< 10 gm/dl) have lower survival time as compared to those who had a high hemoglobin level (≥ 10 gm/dl). The mean (SD) survival time for those having a low hemoglobin level was 47.20 (± 2.84) months and the mean (SD) survival time for those having hemoglobin level ≥ 10 gm/dl was 57.56 (± 0.64) months. The survival time difference between the groups was found statically significant with \( p \)-value < 0.0001.

The mean (SD) survival time for those who had CD4 count below the threshold at baseline was 48.15 (± 2.47) months and 95% CI 43.32–53.00, but it was 57.79 (± 0.60) months and 56.61–58.96 for those who had CD4 count above the threshold at baseline. This difference was statistically significant with \( p \)-value < 0.0001 (Table 3).

### Predictors of mortality among children on ART

The bivariate Cox proportional hazard regression model indicated that age, WHO clinical stage, hemoglobin level, baseline CD4 count, cotrimoxazole preventive therapy (CPT), nutrition status indicators (weight for height, weight for age, and height for age), ART adherence, and regimen change during follow-up were all associated with survival status (\( p < 0.05 \)). However, five variables (age, hemoglobin level, baseline CD4 count, and CPT) were associated with HIV mortality for children on ART in multivariable Cox proportional-hazards model. The result of multivariable analysis revealed that children who were less than 1 year were 8.92 times more likely to die as compared to those of older children ≥5 years (AHR; 8.92, 95% CI:2.62–30.36). Children are aged 1–5 years were also 6.42 times more likely to die as compared to

---

**Table 2 (continued)**

| Variable          | Outcome of the child |   |   | Total n(%) |
|-------------------|----------------------|---|---|------------|
| Severe underweight| Death n(%)           | 4 | 25 | 15        |
|                   | Censored n(%)        | 11| 4.7|           |

---

**Fig. 1** Baseline opportunistic infection of HIV-positive children on ART in East Gojjam zone public hospitals Amhara regional state, Northwest Ethiopia, 2019
Fig. 2  Baseline ART regimen given for HIV-positive children on ART at East Gojjam zone public hospitals Amhara regional state, Northwest Ethiopia, 2019

Fig. 3  The overall Kaplan–Meier survival curve with 95% confidence intervals of children on ART at East Gojjam zone public hospitals Amhara regional state, Northern Ethiopia, 2019
| Covariates                          | Survival time per month, (95% CI) | Log-rank test (p-value) |
|------------------------------------|-----------------------------------|-------------------------|
|                                    | Mean ± SE                         | 95% (CI)                |                         |
| Age in month                       |                                   |                         |
| < 12                               | 39.12 ± 4.25                     | 30.80–47.45             | 19.54 (0.000)           |
| 12–59                              | 50.31 ± 2.52                     | 45.38–55.25             |                         |
| ≥ 60                               | 57.27 ± 4.69                     | 55.92–58.63             |                         |
| Sex                                |                                   |                         |
| Male                               | 55.64 ± 0.94                     | 53.80–57.48             | 2.08 (0.149)            |
| Female                             | 54.38 ± 1.38                     | 51.67–57.09             |                         |
| Residence                          |                                   |                         |
| Urban                              | 54.98 ± 1.16                     | 52.70–57.25             | 0.87 (0.351)            |
| Rural                              | 55.48 ± 1.09                     | 53.33–57.62             |                         |
| CD4 count                          |                                   |                         |
| Below threshold                    | 48.15 ± 2.47                     | 43.32–52.20             | 21.90 (<0.001)          |
| Above threshold                    | 57.79 ± 0.60                     | 56.61–58.96             |                         |
| Hemoglobin level                   |                                   |                         |
| < 10 mg/dl                         | 47.20 ± 2.84                     | 41.63–52.76             | 25.23 (<0.001)          |
| ≥ 10 mg/dl                         | 57.56 ± 0.64                     | 56.31–58.81             |                         |
| WHO HIV stage                      |                                   |                         |
| Stage I                            | 57.04 ± 1.11                     | 54.87–59.21             | 10.23 (0.017)           |
| Stage II                           | 55.85 ± 1.22                     | 53.47–58.23             |                         |
| Stage III                          | 54.31 ± 1.57                     | 51.23–57.40             |                         |
| Stage IV                           | 42.97 ± 3.18                     | 36.73–49.21             |                         |
| Functional status ≥ 5 years        |                                   |                         |
| Working/functional                 | 58.20 ± 0.56                     | 57.11–59.30             | 46.96 (<0.001)          |
| Bedridden                          | 37.50 ± 5.14                     | 27.42–47.58             |                         |
| Ambulatory                         | 57.12 ± 0.87                     | 55.41–58.83             |                         |
| Developmental status (< 5yrs)      |                                   |                         |
| Appropriate                        | 44.49 ± 2.80                     | 39.00–49.98             | 603 (0.819)             |
| Delayed                            | 36.25 ± 3.28                     | 29.83–42.67             |                         |
| Regressed                          | 24.50 ± 4.60                     | 15.49–33.51             |                         |
| Weight for height                  |                                   |                         |
| Normal                             | 57.22 ± 0.71                     | 55.82–58.62             | 17.02 (0.000)           |
| Moderate wasting                   | 52.57 ± 2.08                     | 48.49–56.64             |                         |
| Severe wasting                     | 38.60 ± 5.04                     | 28.73–48.48             |                         |
| Weight for age                     |                                   |                         |
| Normal                             | 57.10 ± 0.76                     | 55.61–58.59             | 15.10 (0.001)           |
| Moderate underweight               | 53.45 ± 1.76                     | 50.01–56.91             |                         |
| Severe underweight                 | 41.20 ± 5.03                     | 31.33–51.06             |                         |
| Height for age                     |                                   |                         |
| Normal                             | 57.17 ± 0.73                     | 55.73–58.60             | 21.79 (<0.001)          |
| Moderate stunting                  | 53.19 ± 1.86                     | 49.54–56.83             |                         |
| Severe stunting                    | 36.67 ± 5.79                     | 25.33–48.01             |                         |
| CPT                                |                                   |                         |
| Yes                                | 57.47 ± 0.68                     | 56.14–58.79             | 10.6 (0.001)            |
| No                                 | 51.06 ± 1.93                     | 47.27–54.85             |                         |
children aged \( \geq 5 \) years (AHR:6.42, 95% CI: 1.40,30.36). Children with a hemoglobin level less than 10 gm/dl were 5.04 times more likely to die as compared to those having hemoglobin level \( \geq 10 \) gm/dl (AHR: 5.04, 95% CI: 1.54–16.55).

Similarly, children having a baseline CD4 count below threshold were 3.55 times more likely to die as compared to those of having a CD4 count above threshold (AHR: 3.55, 95% CI: 1.08–11.67). Children who were not taking cotrimoxazole preventive therapy were at risk of mortality by 2.5 times compared to those who has been taking cotrimoxazole preventive therapy (AHR: 2.5, 95% CI: 1.16–8.20). Furthermore, children who had severe wasting were 5.18 times more likely to die as compared to those who are normal (AHR:5.18, 95% CI: 1.25–21.42) (Table 4).

### Table 3 (continued)

| Covariates          | Survival time per month, (95% CI) Log-rank test (p-value) |
|---------------------|----------------------------------------------------------|
|                     | Mean ± SE | 95% (CI) |                      |
| ART adherence       |            |          |                      |
| Good                | 56.97±0.70 | 55.60–58.35 | 29.33(<0.001) |
| Fair                | 43.34±2.47 | 38.49–48.1  |                      |
| Poor                | 39.16±4.36 | 30.61–47.70 |                      |
| Drug side effect    |            |          |                      |
| Yes                 | 52.26±1.81 | 48.70–55.81 | 0.004 (0.95)  |
| No                  | 55.55±0.96 | 53.67–57.42 |                      |
| Regimen change      |            |          |                      |
| Yes                 | 45.67±4.36 | 37.12–54.23 | 15.10 (0.000) |
| No                  | 56.45±0.75 | 54.99–57.92 |                      |

**Test of proportional hazard assumption**

Testing the proportional hazard (PH) assumption is vital for interpretation and use of fitted proportional hazard models. Therefore, in this study goodness-of-fit (GOF), particularly the Schoenfeld residuals proportional hazard assumption test for the individual covariates and global tests was used. If \( P \)-value<0.05, then the proportional hazard assumption is rejected. The findings indicated that all variables included in the model satisfied PH assumptions (\( p \)-value >0.05) (Table 5).

**Discussion**

This study was aimed to assess survival status and predictors of mortality among HIV-positive children on antiretroviral therapy. Socio-demographic, clinical, nutritional and treatment-related determinant of survival were assessed. The study will be an input to policy-makers, program managers, health professionals to estimate survival rate of patients, to decide based on evidence about HIV/AIDS and to support the planning of systems for enhanced HIV/AIDS control and prevention program.

The result of the study showed that at the end of follow-up, 16 children on ART died and 235 children on ART were censored, resulting in a total death prevalence of 6.37% and an incidence rate of 2.56 per 100 child-years-observation. The overall mortality rate observed in this study was consistent with previous studies done in Ethiopia: 2.1% in Wolaita Zone [11], and 2.3% in Zewditu Memorial Hospital [27]. The nearly similar study periods of the two studies mentioned above with our study might be the reason for agreement of results.

However, the overall mortality rate that occurred in this study was lower than other studies conducted in different countries: India (3%) [28], four sub-Saharan Africa countries (5.1%) [29], Malawi (3.4 deaths per 100 patient years (PYs)) [18], South Africa (4.7 deaths per 100 child years) [30], Eastern Ethiopia (3.8 per 1000 child-months) [13], Northwest Ethiopia (4% CYO) [7], and Arba Minich (3.6% CYO) [8]. This discrepancy might be due to difference in the study period as there were changes in treatment modality recently recommended to treat all HIV-positive children regardless of their WHO clinical stage and CD4 count. Another possible reason might be the difference in the stage of HIV/AIDS at ignition of ART. In this study, the majority of the study participants started ART at WHO clinical stage (I and II) but not in others. Children who were initiated ART at early phase had a longer survival time as compared to their counterparts. Furthermore, the differences of the results might be the difference in the duration study. Another possible explanation might be the difference in sample size. There were also studies which reported lower findings; in Nigeria (1%) [31], in Addis Ababa (12.4 deaths per 1000 child-year) [12], and in Mekelle, Ethiopia (1.40 per 1000 child-months) [32].
In this study, age was found to be a significant predictor of mortality among HIV-positive children on ART. The mortality rate was higher among the youngest children less than 5 years than among older children. Children < 1-year-old were 8.92 times more likely to die as compared to children ≥ 5 years old. This finding was consistent with other previous studies conducted in Swaziland [33], India [28], Nigeria [31, 34], Malawi [18], and Ethiopia [9, 10, 27]. Children 1–5 years old were also 6.42 times more likely to die as compared to children ≥ 5 years old. This finding was consistent with another previous study conducted in Ethiopia [9]. This fragility of infants and younger children that ended up might have resulted in high mortality rate among

### Table 4  Cox regression analysis of predictors of mortality among children on ART at East Gojjam zone public hospitals, Amhara regional state, North West Ethiopia, 2019 (N=251)

| Variables                  | Death N (%) | Censored N (%) | CHR (95% CI)          | AHR (95% CI)          | p-value |
|----------------------------|-------------|----------------|-----------------------|-----------------------|---------|
| **Age**                    |             |                |                       |                       |         |
| < 1 year                   | 4 (25)      | 15 (6.4)       | 10.57(2.94, 8.02)     | 8.92(2.62,30.36)      | 0.000   |
| 1–5 year                   | 6 (37.5)    | 47 (20.0)      | 4.54 (1.46, 14.16)    | 6.42 (1.4, 29.5)      | 0.017   |
| ≥ 5 year                   | 6 (37.5)    | 173 (73.6)     | 1                     | 1                     |         |
| **CD4 count**              |             |                |                       |                       |         |
| Below threshold            | 12 (75)     | 52 (23.0)      | 9.27 (2.98, 28.76)    | 3.55(1.08, 11.67)     | 0.037   |
| Above threshold            | 4 (25)      | 174 (77.0)     | 1                     | 1                     |         |
| **Hemoglobin**             |             |                |                       |                       |         |
| < 10 mg/dl                 | 11 (68.8)   | 40(17.2)       | 9.26(2.98, 28.76)     | 5.04(1.54, 16.55)     | 0.008   |
| ≥ 10 mg/dl                 | 5 (31.2)    | 193 (82.8)     | 1                     | 1                     |         |
| **Baseline WHO stage**     |             |                |                       |                       |         |
| Stage I & II               | 6 (37.5)    | 149 (63.4)     | 0.36(0.13, —0.99)     | 0.45(0.16, 1.28)      | 0.113   |
| Stage III & IV             | 10 (62.5)   | 86 (36.6)      | 1                     | 1                     |         |
| **Taking CPT**             |             |                |                       |                       |         |
| Yes                        | 5 (31.3)    | 178 (75.7)     | 1                     | 1                     |         |
| No                         | 11 (68.8)   | 57 (24.3)      | 4.95 (1.71, 14.30)    | 2.5(1.16, 8.20)       | 0.034   |
| **Opportunistic infections** |          |                |                       |                       |         |
| Yes                        | 10 (62.5)   | 65 (27.7)      | 3.78 (1.37, 10.38)    | 2.18(0.63, 7.57)      | 0.222   |
| No                         | 6 (37.5)    | 170 (72.3)     | 1                     | 1                     |         |
| **Weight for height**      |             |                |                       |                       |         |
| Normal                     | 6 (37.5)    | 178 (75.7)     | 1                     | 1                     |         |
| Moderate wasting           | 4 (25.0)    | 52 (22.1)      | 2.07 (0.58, 7.35)     | 1.82(0.53, 6.16)      | 0.336   |
| Sever wasting              | 6 (37.5)    | 5 (2.1)        | 21.39 (6.86, 66.72)   | 5.18(1.25, 21.42)     | 0.023   |
| **Height for age**         |             |                |                       |                       |         |
| Normal                     | 6 (37.5)    | 171 (72.8)     | 1                     | 1                     | 0.996   |
| Moderate stunting          | 6 (37.5)    | 56 (23.8)      | 2.71(0.87, 8.40)      | 1.01(0.01,241.00)     | 0.998   |
| Sever stunting             | 4 (25.0)    | 8 (3.4)        | 12.24(3.44, 43.59)    | 0.70(0.01,1476.91)    | 0.928   |
| **Weight for age**         |             |                |                       |                       |         |
| Normal                     | 6 (37.5)    | 165 (70.2)     | 1                     | 1                     |         |
| Under weight               | 6 (37.5)    | 59 (25.1)      | 2.45 (0.79, 7.59)     | 2.33(0.54, 6.41)      | 0.431   |
| Sever under weight         | 4 (25.0)    | 11 (4.7)       | 8.89 (2.49, 31.66)    | 2.66(0.65, 13.45)     | 0.311   |
| **ART adherence**          |             |                |                       |                       |         |
| Good                       | 8 (50.0)    | 209 (88.9)     | 1                     | 1                     |         |
| Fair                       | 2 (12.5)    | 17 (7.2)       | 2.72 (0.58, 12.83)    | 1.27(0.65, 8.22)      | 0.847   |
| Poor                       | 6 (37.5)    | 9 (3.8)        | 10.89 (3.76, 15.4)    | 1.49(0.83, 7.54)      | 0.733   |
| **The regimen changed**    |             |                |                       |                       |         |
| No                         | 11 (68.8)   | 225 (95.7)     | 6.26 (2.17, 18.07)    | 5.62(2.34, 82)        | 0.972   |
| Yes                        | 5 (31.3)    | 10 (4.3)       | 1                     | 1                     |         |

Values in bold font are used to highlight factors with statistically significant impact on survival.
children in this age group. Children starting ART before 2 years of age are more likely to have rapid disease progression [31] and this may also be the cause of high mortality in the young children. Further research is needed to identify factors impacting health outcomes among this highly vulnerable group of children. However, this study does not support a study done in Uganda which stated there was no enough evidence to suggest that age had a confounding effect on survival [16].

Children with CD4 count below the threshold level at initiation of ART have higher risk of death (3.55 times) than those children with CD4 count above the threshold. This might be due to the fact that HIV attacks CD4 cells, as a result child with the lower CD4 count could have the chances of acquiring serious diseases which leads to death. This finding is consistent with previous studies conducted in different areas of Ethiopia [6–8, 10, 34]. On the contrary, a study done in Bahir-Dar found that low baseline CD4 cell count was not a predictor of survival time of HIV-infected children [9].

Similarly, in this study the risk of mortality increased among children with low hemoglobin level at baseline. Children with low hemoglobin level (<10 gm/dl) were 5.04 times at risk of death as compared with their counterparts. This study was supported by other findings [6–10]. This might be due to the dual effect of anemic condition and some drugs that aggravate anemia which leads to other comorbidity and death.

The findings of present study revealed that malnutrition in the form of severe wasting was a significant predictor of mortality among children on ART. Children who were severely wasted at the time of ART initiation were 5.18 times more likely to die as compared to those who were normal (not wasted) at the time of ART initiation. This finding is consistent with other previous studies [31, 33]. However, baseline nutritional status was not significant predictor of mortality [7].

In this study, cotrimoxazole preventive therapy was found to be an independent predictor of survival that becomes statistically significant in the Cox proportional hazard model. Cotrimoxazole was found to have a protective effect for children on ART (AHR=2.5, 95% CI:1.16-8.20). This finding is consistent with previous findings of different studies [7, 27]. This finding is also supported by WHO recommendation that states all exposed infants and HIV-infected children to start CPT [35].

Unlike most of previous findings [6, 9, 10, 13, 27, 29, 31, 34], it was found that WHO clinical-stages at baseline were not found to be an independent predictors of survival in this study. This discrepancy could be owing to changes in treatment modality recommended to treat all HIV-positive children regardless of their WHO clinical stage and CD4 count. As a result, this cohort reveals a high proportion child were in mild baseline WHO clinical-stages (stages I and II). This study is in line with a previous study done in Ethiopia [7].

**Conclusion and recommendation**

This study found that the overall mortality rate was 2.56 per 100 children years observation. The mortality rate was lower when compared with previous studies done in Ethiopia as well as other countries. CD4 count below threshold, children aged <1 year and 1–5 years, baseline malnutrition in the form of severe wasting (WFH < 3z), not taking cotrimoxazole preventive therapy, and baseline Hgb < 10 gm/dl were significant predictors of mortality among HIV-positive children after initiation of ART.

Close monitoring and follow-up should be given for under-five, malnourished and anemic children. Furthermore, the current guideline on the initiation of CPT needs to be revised as children who are not taking CPT are more likely to have lower survival status. It is recommended to conduct prospective cohort studies to better understand the impact of each factor affecting survival status of children on ART.

**Limitations of the study**

The findings of this study should be interpreted with consideration of the following conditions: initially the study was a retrospective follow-up study and secondly the number of study subjects was small as compared to the calculated sample size due to the smaller number of children on ART at the two study sites. Moreover, some children who were lost to follow-up were not addressed by tracing mechanism, which may under estimate mortality rate as they might end up in death.

| Variable         | Rho | Chi2  | Df | Prob > Chi2 |
|------------------|-----|-------|----|-------------|
| Age              | 0.03| 0.01  | 1  | 0.90        |
| Hemoglobin       | 0.15| 0.49  | 1  | 0.48        |
| CD4 count        | −0.05| 0.07  | 1  | 0.79        |
| Weight for height| −0.24| 0.06  | 1  | 0.80        |
| Height for age   | 0.17| 0.06  | 1  | 0.81        |
| Weight for age   | 0.10| 0.2   | 1  | 0.90        |
| WHO stage        | −0.14| 0.37  | 1  | 0.54        |
| CPT              | 0.10| 0.17  | 1  | 0.68        |
| OI               | −0.22| 0.69  | 1  | 0.40        |
| ART adherence    | 0.17| 0.61  | 1  | 0.44        |
| The regimen changed | −0.25| 1.40  | 1  | 0.24        |
| global test      | 11.96| 11.1  | 11 | 0.37        |
Author contributions
YB and BG conceptualized and designed the study; AW and MG participated in data collection and analysis; YB and KW interpreted findings of the study. All authors read and approved the final manuscript and agreed to submit to Journal of Pharmaceutical Policy and Practice.

Funding
This study was sponsored by Addis Ababa University.

Availability of data and materials
Please contact the corresponding author for data requests.

Declarations

Ethics approval and consent to participate
An ethical clearance letter was obtained from the Institutional Review Board of School of Nursing and Midwifery, College of Health Science, Addis Ababa University. Permission was obtained from Debere Markos referral hospital and Shegaw Mota district hospital. All collected data were coded to keep confidentiality. Names and unique numbers of patients were not included in the data collection format, and the data were not disclosed to any person other than the investigators.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1School of Nursing and Midwifery, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia. 2Department of Pediatrics and Child Health Nursing, College of Health Sciences, Debere Markos University, Debere Markos, Ethiopia. 3Department of Pharmacy, College of Health Sciences, Debere Markos University, Debere Markos, Ethiopia.

Received: 8 June 2022 Accepted: 8 August 2022
Published online: 17 August 2022

References
1. UNAIDS. Factsheet—World AIDS day: 2017 Global HIV Statistics. 2018. https://www.unaids.org/sites/default/files/media_asset/unaids-data-2018_en.pdf.
2. UNAIDS. Full report—in danger: UNAIDS Global AIDS Update 2022. Available at: https://www.unaids.org/en/resources/documents/2022/indanger-global-aids-update.
3. World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV: World Health Organiza- tion, 2015. Available at: https://apps.who.int/iris/bitstream/handle/10665/186275/9789241509565_eng.pdf.
4. Ethiopia FMoH. National guidelines for comprehensive HIV prevention, care and treatment. AAMo Health. 2017. Available at: https://www.childrenandaidsofnode/526.
5. HAPCO, Ethiopia FMoH. Report on Progress towards Implementation of the UN Declaration of Commitment on HIV/AIDS. AA.; 2010. Available at: https://www.unaids.org/sites/default/files/country/documents/ethiopia_2010_country_progress_report_en.pdf.
6. Kedir AA, Desta A, Fesseha G. Factors affecting survival of HIV positive children taking antiretroviral therapy at Adama referral hospital and medical college, Ethiopia. AIDS Clin Res. 2014;5:3.
7. Koye DN, Ayele TA, Zeleke BM. Predictors of mortality among children on antiretroviral therapy at a referral hospital. Northwest Ethiopia BMC Pediatr. 2012. https://doi.org/10.1186/1471-2431-12-161.
8. Sidamo NB, Debere MK, Endersi BO, Abyu DM. Incidence and predictors of mortality among children on anti-retroviral therapy in public health facilities of Arba Minch Town, Gamo Gofa Zone. Southern Ethiopia Clin Mother Child Health. 2017;143.
9. Atanu H, Wencheko E. Factors affecting the survival of HIV-infected children after ART initiation in Bahir-Dar, Ethiopia. Ethiop J Health Dev. 2015;29(Suppl):115705.
10. Andargie A, Asmelash Y. Survival time of human immunodeficiency virus (HIV) infected children under 15 years of age after initiation of antiretrovir- al therapy in the University of Gondar Comprehensive Specialized Hospital, Ethiopia. J AIDS HIV Res. 2018;10(4):49–55.
11. Bitew S, Mekonen A, Assegid M. Predictors on mortality of human immunodeficiency virus infected children after initiation of antiretroviral treatment in Wolaita zone health facilities, Ethiopia. J AIDS HIV Res. 2017;9(4):89–97.
12. Dube L, Mulugeta A, Assefa H, Tewelde T. Determinants of survival among hiv positive children on antiretroviral therapy in public hospita- tals, Addis Ababa Ethiopia. Qual Primary Care. 2017;25(4):235–41.
13. Edessa D, Aseta F, Sheikahmed J. Early mortality among HIV-positive children initiated anti-retroviral therapy in Eastern Ethiopia. Sci Technol Arts Res J. 2015;4(2):157–63.
14. Wamalwa DC, Obimbo EM, Farquhar C, et al. Predictors of mortality in HIV-1 infected children on antiretroviral therapy in Kenya: a prospective cohort. BMC Pediatr. 2010. https://doi.org/10.1186/1471-2431-10-33.
15. Gultie T, et al. Factors affecting adherence to pediatrics antiretroviral therapy in Mekelle hospital, Tigray Ethiopia. LIPHS. 2015;4(1):1–6.
16. Massawon V, Barlow-Mosha L, Mugenzi L, McFarland W, Gray G, Lundin R, Costenaro P, Nannoyunga MM, Penazzato M, Taginda D, Namisi CP. Factors determining survival and retention among HIV-infected children and adolescents in a community home-based care and a facility-based family-centred approach in Kampala, Uganda: a cohort study. Int Sch Res Not. 2014;2014.
17. Mwiru RS, Spiegelman D, Duggan C, et al. Nutritional status and other baseline predictors of mortality among HIV-infected children initiating antiretroviral therapy in Tanzania. JAPAC. 2015;14(2):172–9.
18. Brophy JC, Hawkes MT, Miwiniwia E, Mateyug S, Sodzi SK, Chan AK. Survival outcomes in a pediatric antiretroviral treatment cohort in Southern Malawi. PLoS ONE. 2016. https://doi.org/10.1371/journal.pone.0165772.
19. Gesesew HA, Ward P, Woldemichael K, Mwanli L. Early mortality among children and adults in antiretroviral therapy programs in Southwest Ethiopia, 2003–15. PLoS ONE. 2018. https://doi.org/10.1371/journal.pone.0198815.
20. Vermund SH, Blevins M, Moon TD, Jose E, Moiane L, et al. Poor clinical outcomes for hiv infected children on antiretroviral therapy in rural mozambique: need for program quality improvement and community engagement. PLoS ONE. 2014;9(10):e101116.
21. Central Statistical Agency [Ethiopia]. Population projection of Ethiopia for all regions at wereda level from 2014–2017. Addis Ababa, Ethiopia, 2015.
22. Fenta A, Demeke G, Bitew A, Kebede D, Hailu T. Determinants of survival outcomes for hiv infected children on antiretroviral therapy in rural northwest ethiopia: a five-year retrospective cohort study. AIDS Res Treat. 2017;2017:3216205.
23. Gultie T, et al. Factors affecting adherence to pediatrics antiretroviral therapy in Mekelle hospital, Tigray Ethiopia. LIPHS. 2015;4(1):1–6.
24. Ethiopia FMoH. National guidelines for comprehensive HIV prevention, care and treatment. (2018). Ethiopian Ministry of Health. 2018. Available at: https://www.afro.who.int/sites/default/files/2019-04/National% 20Comprehensive%20HIV%20Care%20Guideline%202018.pdf.
25. World Health Organization. WHO child growth standards. Geneva: World Health Organization, 2006.
26. Turk D, Michaelesen KF, Shamir R, et al. World health organization 2006 child growth standards and 2007 growth reference charts a discussion paper by the committee on nutrition of the European society for pedi- atric gastroenterology, hepatology, and nutrition. J Pediatr Gastroen- terol Nutr. 2013;57(2):258–64.
27. Mokgatlle M, Abasho D. Treatment outcomes of antiretroviral therapy among pediatric patients in Zewditu Memorial Hospital, Addis Ababa, Ethiopia. PULA Botswana J Afr Stud. 2016;30(1):11.

28. Jha U, Dhingra N, Raj Y, et al. Survival of children living with human immunodeficiency virus on antiretroviral therapy in Andhra Pradesh, India. Indian Pediatr. 2018;55:301–5.

29. Ben-Farhat J, Schramm B, Nicolay N, et al. Mortality and clinical outcomes in children treated with antiretroviral therapy in four African vertical programs during the first decade of paediatric HIV care 2001–2010. Trop Med Int Health. 2017. https://doi.org/10.1111/tmi.12830.

30. Zanoni BC, Phungula T, Zanoni HM, France H, et al. Risk Factors Associated with Increased Mortality among HIV Infected Children Initiating Antiretroviral Therapy (ART) in South Africa. PLoS ONE. 2011;6(7):e22706. https://doi.org/10.1371/journal.pone.0022706.

31. Ebonyi AO, Meloni S, Oguche S, et al. Predictors of mortality in a clinic cohort of HIV-1 infected children initiated on antiretroviral therapy in Jos, Nigeria. J AIDS Clin Res. 2014. https://doi.org/10.4172/2155-6113.1000403.

32. Gebremedhin A, Gebremariam S, Haile S, Weldearegawi B, Decotelli C. Predictors of mortality among HIV-infected children on anti-retroviral therapy in Mekelle Hospital, Northern Ethiopia. BMC Public Health. 2013. https://doi.org/10.1186/1471-2458-13-1047.

33. Shabangu P, Beke A, Manda S, Mabethwa N. Predictors of survival among HIV-positive children on ART in Swaziland. Afr J AIDS Res. 2017;16(4):335–43.

34. Ojeniran MA, Emokpae A, Mabogunje C, Akintan P, Hoshen M, Weiss R. How are children with HIV faring in Nigeria? BMC Pediatr. 2015;15(87):1–7.

35. WHO, UNICEF. Co-trimoxazole prophylaxis for HIV-exposed and HIV-infected infants and children: Practical approaches to implementation and scale up. Geneva: WHO; 2009.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.